Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
Original Publication Date
Article Source
External Web Content
Key Points Prolonged ruxolitinib administration after allogeneic HCT is associated with low rates of clinically significant chronic GVHD. Abstract Despite recent advances in graft-versus-host disease (GVHD) prophylaxis, novel approaches to effective prevention of chronic GVHD…
